$695 | Single User
$1395 | Global License

Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?

Published by FirstWord Pharma: 25 Feb 2015 | 192 | In Stock

Introduction

Scope



Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight the potential cost of treatment to the US healthcare system associated with a new class of dyslipidaemia therapies called PCSK9 inhibitors. The two most advanced drugs in this class – Sanofi and Regeneron Pharmaceuticals' alirocumab and Amgen's evolocumab – are widely expected to gain FDA approval during the second half of 2015.


Two key points arise from CVS' eye-watering assertion that the PCSK9 class could cost the US system up to 0 billion a year; whether such public assessments are now the 'new normal' in a post-Sovaldi payer environment and whether anticipated physician usage of these new drugs supports the estimation provided by CVS? - ViewPoints: CVS Health gets the math wrong, but is it the thought that counts?


Feedback sourced from physicians by FirstWord over the past few years indicates that the cost estimate provided by CVS represents a worst-case scenario by some margin. Nevertheless, we thought it useful to poll US-based cardiologists this week in light of the potential significance that payer stance towards the PCSK9s could have on these anticipated blockbuster products and potentially other drug classes.


Puchase Reasons


Specifically we are asking US-based cardiologists:


Despite the broad popularity of this drug class, there remains significant scope to optimise the use of statin therapy in patients who may initially be deemed intolerant or who may be presumed unlikely to reach LDL goal with a statin.

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree

  • Thinking about launch of the first PCSK9 inhibitors later this year, PBMs and other payers will be right to attempt to limit access by requiring laboratory tests to show evidence of muscle inflammation or liver damage before allowing treatment to those deemed statin intolerant.

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree

  • Recently introduced guidelines from the American Heart Association and American College of Cardiology – which suggest that those patients who have had a previous cardiac event should be treated initially with high-dose statins to lower cholesterol as much as possible – will significantly increase my use of the PCSK- inhibitor class among patients with a history of coronary artery disease.

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree

  • Assuming that outcomes studies demonstrate positive results, to what percentage of patients with heterozygous familial hypercholesterolaemia (HeFH) would you expect to prescribe a PCSK9 inhibitor (at peak usage)?

    Excluding uncertainty as to whether the PCSK9 inhibitor class will demonstrate a cardiovascular outcomes benefit (data should be available in the 2017-2018 timeframe), what would act as the primary reason for you not to prescribing one of these drugs?

  • Sub-optimal use of statin therapy

  • Injectable administration of PCSK9s

  • Cost

  • Unfamiliarity with drug class

  • Other (please state)
  • Table of Contents
    for Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    192 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data